ISTA Pharma (ISTA) Reports Positive Results from BEPOSONE Phase 2

ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) reports positive results from its Phase 2 randomized, placebo-controlled, parallel-group environmental clinical study of BEPOSONE" (bepotastine besilate/steroid) nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. According to the trial findings, BEPOSONE nasal spray showed highly statistically significant improvements compared to placebo in patients' nasal symptoms following exposure to one of the most potent seasonal allergy triggers, Mountain Cedar pollen. These improvements were seen as early as Day 1 of therapy and were sustained through the two-week treatment period. Statistically significant improvement was also seen for BEPOSONE within 15 minutes after dosing in a small subgroup of subjects who frequently evaluated their nasal symptoms for 4 hours after their first nasal spray dose. Further, safety data demonstrated BEPOSONE was well-tolerated as a nasal spray, with an adverse event profile similar to placebo and generally consistent with those observed with bepotastine besilate dosed as a nasal spray in prior clinical trials and with other antihistamine nasal sprays.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Revolution Medicines prices RASONQUE at $39,800 per month
• Salesforce and Anthropic launch Claudeforce CRM integration
• Atlantic American gets Nasdaq notice over multiple late filings